Fixeddose combination of rosuvastatin + ezetimibe: ease of use, safety and efficacy

Today, cardiovascular diseases remain the leading cause of morbidity and mortality globally. Hyperlipidemia and dyslipidemia are key points in the occurrence and progression of CVDs, as well as the development of its complications. Elevated low density lipoprotein cholesterol (LDL-C) is the target of lipid-lowering therapy. The LDL-C target level is often not achieved in everyday clinical practice, which is especially important for patients at high and very high risk for cardiovascular complications. Furthermore, in some patient subgroups, atherogenic dyslipidemia is observed. Due to use of intensive and prolonged lipid-lowering therapy, the problem of its tolerability and patient adherence to the treatment becomes a live issue today. In addition, the use of drugs with effect that complements and enhances the effect of statin helps to achieve targets and improve long-term prognosis. Statins and ezetimibe are effective and widely used drugs to treat dyslipidemia. Clinical studies show that ezetimibe can be safely co-administered with statins to enhance lipid-lowering activity. In this regard, a statin and non-statin drug fixed-dose combination tablet may have additional advantages both for enhancing the lipidlowering effect and for greater patient convenience. Rosuvastatin is more effective than other statins in reducing low density lipoprotein cholesterol. The article provides a rationale for the possibility, efficacy, safety and convenience of using an ezetimibe and rosuvastatin fixed-dose combination tablet in patients with a high and very high risk and unattained target level of low density lipoprotein cholesterol.

dyslipidemia, lipid-lowering drugs, low-density lipoprotein cholesterol, rosuvastatin, ezetimibe, fixed-dose combination of drugs, target lipid level

1. Yach D., Hawkes C., Gould C.L., Hofman K.J. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA. 2004;291(21):2616-2622. doi: 10.1001/ jama.291.21.2616.

2. WHO Newsletter on 17/May/2017. Bulletin of the World Health Organization. 2017;95(5):313- 388. Available at: https://www.who.int/bulletin/ volumes/95/5/en.

3. Catapano A.L., Graham I., De Backer G., Wiklund O., Chapman M.J., Drexel H., Hoes A.W., Jennings C.S. , Landmesser U., Pedersen T.R., Reiner Ž., Riccardi G., Taskinen M.-R., Tokgozoglu L., Verschuren W.M.M., Vlachopoulos Ch., Wood D.A., Zamorano J.L., Cooney M.-Th., ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2016;37:2999–3058. doi: 10.1093/eurheartj/ehw272.

4. Stone N.J., Robinson J.G., Lichtenstein A.H., C. Noel Bairey Merz, Blum C.B., Eckel R.H., Goldberg A.C., Gordon D., Levy D., Lloyd-Jones D.M., McBride P., Schwartz J.S., Shero S.T., Smith S.C. Jr., Watson K., Wilson P.W.F. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1-S45. doi: 10.1161/01.cir.0000437738.63853.7a.

5. Ежов М.В., Сергиенко И.В., Аронов Д.М., Арабидзе Г.Г., Ахмеджанов Н.М., Бажан С.С., Балахонова Т.В., Барбараш О.Л., Бойцов С.А., Бубнова М.Г., Воевода М.И., Галявич А.С., Горнякова Н.Б., Гуревич В.С., Драпкина О.М., Дупляков Д.В., Ерёгин С.Я., Зубарева М.Ю., Карпов Р.С., Карпов Ю.А., Козиолова Н.А., Коновалов Г.А., Константинов В.О., Космачева Е.Д., Мартынов А.И., Небиеридзе Д.В., Покровский С.Н., Рагино Ю.И., Скибицкий В.В., Смоленская О.Г., Чазова И.Е., Шальнова С.А., Шапошник И.И., Кухарчук В.В. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VI пересмотр, Москва, 2017 год. Атеросклероз и дислипидемии. 2017;(3):5-22. Режим доступа: http://webmed.irkutsk.ru/doc/pdf/noa.pdf. Ezhov M.V., Sergienko I.V., Aronov D.M., Arabidze G.G., Akhmedzhanov N.M., Bazhan S.S., Balakhonova T.V., Barbarash O.L., Boytsov S.A., Bubnova M.G., Voevoda M.I., Galyavich A.S., Gornyakova N.B., Gurevich V.S., Drapkina O.M., Duplyakov D.V., Yeregin S.Ya., Zubareva M.Yu., Karpov R.S., Karpov Yu.A., Koziolova N.A., Konovalov G.A., Konstantinov V.O., Kosmacheva E.D., Martynov A.I., Nebieridze D.V., Pokrovsky S.N., Ragino Yu.I., Skibitsky V.V., Smolenskaya O.G., Chazova I.E., Shalnova S.A., Shaposhnik I.I., Kukharchuk V.V. Diagnostics and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Revision VI. Ateroskleroz i Dislipidemii = The Journal of Atherosclerosis and Dyslipidemias. 2017;(3):5-22. (In Russ.) Available at: http://webmed.irkutsk. ru/doc/pdf/noa.pdf.

6. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B. Jr, Clark L.T., Hunninghake D.B., Richard C. Pasternak , Sidney C. SmithJr , Neil J. Stone. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation. 2004;110(2):227-239. doi: 10.1161/01. CIR.0000133317.49796.0E

7. Piepoli M.F., Hoes A.W., Agewall S., Albus C., Brotons C., Catapano A.L., Cooney M.T., Corrà U., Cosyns B., Deaton C., Graham I., Hall M.S., Hobbs F.D.R., Løchen M.L., Löllgen H., MarquesVidal P., Perk J., Prescott E., Redon J., Richter D.J., Sattar N., Smulders Y., Tiberi M., van der Worp H.B., van Dis I., Verschuren W.M.M., Binno S.; ESC Scientific Document Group.2016 European Guidelines on cardiovascular disease prevention in clinical practice The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Eur Heart J. 2016;37(29):2315-2381. doi: 10.1093/eurheartj/ehw106.

8. Euroaspire II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001;22(7):554- 572. doi: 10.1053/euhj.2001.2610.

9. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., Peto R., Barnes E.H., Keech A., Simes J., Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5

10. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278. doi: 10.1016/ S0140-6736(05)67394-1.

11. Cannon C.P., Steinberg B.A., Murphy S.A., Mega J.L., Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48(3):438-445. doi: 10.1016/j. jacc.2006.04.070.

12. National Institute for Health and Care Excellence. Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. National Institute for Health and Care Excellence; 2014. NICE Clinical guideline 181. Available at: https:// www.ncbi.nlm.nih.gov/pubmed/25340243.

13. Kotseva K., Wood D., De Bacquer D., De Backer G., Rydén L., Jennings C., Gyberg V., Amouyel P., Bruthans J., Castro Conde A., Cífková R., Deckers J.W., De Sutter J., Dilic M., Dolzhenko M., Erglis A., Fras Z., Gaita D., Gotcheva N., Goudevenos J., Heuschmann P., Laucevicius A., Lehto S., Lovic D., Miličić D., Moore D., Nicolaides E., Oganov R., Pajak A., Pogosova N., Reiner Z., Stagmo M., Störk S., Tokgözoğlu L., Vulic D. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur. J. Prev. Cardiol. 2016 Apr;23(6):636–648. doi: 10.1177/2047487315569401.

14. De Backer G., Jankowski P., Kotseva K., Mirrakhimov E., Reiner Ž., Rydén L., Tokgözoğlu L., Wood D., De Bacquer D. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135–146. doi: 10.1016/j.atherosclerosis.2019.03.014.

15. Pearson T.A., Laurora I., Chu H., Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160(4):459-467. doi: 10.1001/ archinte.160.4.459.

16. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003 Jun 28;326(7404):1423. doi: 10.1136/ bmj.326.7404.1423.

17. Kapur N.K. Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease. Expert Rev Cardiovasc Ther. 2007;5(2):161-175. doi: 10.1586/14779072.5.2.161.

18. Luvai A., Mbagaya W., Hall A.S., Barth J.H. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol. 2012;6:17-33. doi: 10.4137/CMC.S4324.

19. Schuster H., Fox J.C. Investigating cardiovascular risk reduction–the Rosuvastatin GALAXY Programme. Expert. Opin. Pharmacother. 2004;5(5):1187–1200. doi: 10.1517/14656566.5.5.1187.

20. Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert. Rev. Cardiovasc. Ther. 2007;5(2):177–193. doi: 10.1586/14779072.5.2.177.

21. Huff M.W., Pollex R.L., Hegele R.A. NPC1L1: evolution from pharmacological target to physiological sterol transporter. Arterioscler Thromb Vasc Biol. 2006;26(11):2433-2438. doi: 10.1161/01.ATV.0000245791.53245.ee.

22. Pandor A., Ara R.M., Tumur I., Wilkinson A.J., Paisley S., Duenas A., Durrington P.N., Chilcott J. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med. 2009 May;265(5):568-80. doi: 10.1111/j.1365-2796.2008.02062.x.

23. Ballantyne C.M., Houri J., Notarbartolo A., Melani L., Lipka L.J., Suresh R., Sun S, LeBeaut AP, Sager PT, Veltri EP. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107(19):2409-2415. doi: 10.1161/01. CIR.0000068312.21969.C8.

24. Davidson M.H., McGarry T., Bettis R., Melani L., Lipka L.J., LeBeaut A.P., Suresh R., Sun S., Veltri E.P. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40(12):2125- 2134. doi: 10.1016/s0735-1097(02)02610-4.

25. Angelopoulos J., Krassakopoulos N., Nathanson R., Boukas S., Sampalis J.S. Co-administration of ezetimibe and a statin in management of dyslipidemias: a meta-analysis of clinical trials. Arch Med Sci. 2009;5:347–363. Режим доступа: https://www.termedia.pl/Clinical-research-Coadministration-of-ezetimibe-and-a-statin-inmanagement-of-dyslipidemias-a-meta-analysis-of-clinical-trials,19,13473,0,1.html.

26. Morrone D., Weintraub W.S., Toth P.P., Hanson M.E., Lowe R.S., Lin J., Shah AK, Tershakovec AM. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223(2):251-61. doi: 10.1016/j.atherosclerosis.2012.02.016

27. Bays H.E., Davidson M.H., Massaad R., Flaim D., Lowe R.S., Tershakovec A.M., Jones-Burton C. Safety and Efficacy of Ezetimibe Added on to Rosuvastatin 5 or 10 mg Versus Up-Titration of Rosuvastatin in Patients With Hypercholesterolemia (the ACTE Study). Am J Cardiol. 2011;108:523–530. doi: 10.1016/j.amjcard.2011.03.079.

28. Ballantyne C.M., Weiss R., Moccetti T., Vogt A., Eber B., Sosef F., Duffield E. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007;99(5):673-680. doi: 10.1016/j.amjcard.2006.10.022.

29. Min K.L., Park M.S., Jung J., Chang M.J., Kim C.O. Comparison of pharmacokinetics and safety of a fixed-dose combination of rosuvastatin and ezetimibe versus separate tablets in healthy subjects. Clin Ther. 2017;39(9):1799-1810. doi: 10.1016/j.clinthera.2017.07.038.

30. Kim K.J., Kim S.H., Yoon Y.W., Rha S.-W., Hong S.J., Kwak C.H., Nam C.W., Rhee M.Y., Park T.H., Hong T.J., Park S., Ahn Y., Lee N., Jeon H.K., Jeon D.W., Han K.R., Moon K.W., Chae I.H., Kim H.S. Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). Cardiovasc Ther. 2016;34(5):371-382. doi: 10.1111/1755-5922.12213.

31. Hong S.J., Jeong H.S., Ahn J.C., Cha D.H., Won K.H., Kim W., Cho S.K., Kim S.Y., Yoo B.S., Sung K.C., Rha S.W., Shin J.H., Han K.R., Chung W.S., Hyon M.S., Lee H.C., Bae J.H., Rhee M.Y., Kwan J., Jeon D.W., Yoo K.D., Kim H.S. A phase III, multicenter, randomized, double-blind, active comparator clinical trial to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus rosuvastatin monotherapy in patients with hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) randomized controlled trial. Clin Ther. 2018;40(2):226-241.e224. doi: 10.1016/j. clinthera.2017.12.018.

32. Cannon C.P., Blazing M.A., Giugliano R.P., McCagg A., White J.A., Theroux P., Darius H., Lewis B.S., Ophuis T.O., Jukema J.W., De Ferrari G.M., Ruzyllo W., De Lucca P., Im K., Bohula E.A., Reist C., Wiviott S.D., Tershakovec A.M., Musliner T.A., Braunwald E., Califf R.M. IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-2397. doi: 10.1056/ NEJMoa1410489.

33. Bohula E.A., Morrow D.A., Giugliano R.P., Blazing M.A., Ping He, Park J.G., Murphy S.A., White J.A., Kesaniemi Y.A., Pedersen T.R., Brady A.J., Mitchel Y., Cannon C.P., Braunwald E. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. J Am Coll Cardiol. 2017;69(8):911-21. doi: 10.1016/j.jacc.2016.11.070.

34. Lloyd-Jones D.M., Morris P.B., Ballantyne C.M., Birtcher K.K., Daly Jr. D.D., DePalma S.M., Minissian M.B., Orringer C.E., Smith S.C. Jr. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70(14):1785- 822. doi: 10.1016/j.jacc.2017.07.745.